Letter
Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Study conclusions do not reflect findings for celecoxib
BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7530.1473-d (Published 15 December 2005) Cite this as: BMJ 2005;331:1473
- Joe Feczko, chief medical officer (rscmoppgp-JoeFeczko@pfizer.com)
- Pfizer, New York, NY 10017, USA
EDITOR—The conclusions drawn by Hippisley-Cox et al do not accurately reflect the data as presented.1
This study found important differences between celecoxib and the studied non-steroidal anti-inflammatory drugs (NSAIDs) in terms of the risk of adverse gastrointestinal effects. Specifically, celecoxib was the only treatment that did …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.